Rick Schneider is a family man — a husband and doting father to three girls. He’s also an outdoorsman who loves to bike, hike ...

Infiltrating Lymphocyte Scoring Improves Progression Risk Prediction in Stage II Melanoma: A Retrospective Cohort Study,” published in the March 2025 issue of Journal of the American Academy of ...

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines.

Through this agreement, Xcellbio scientists will work with the Royal Perth Hospital team to develop an automated TIL manufacturing process based on AVATAR platform that achieves key goals for cell ...

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid ...

Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...

Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a platform company focused on cell and gene therapy applications, and Royal Perth Hospital announced a ...

Instil Bio is pivoting from tumor-infiltrating lymphocytes to in-licensed bispecifics, targeting PD-L1 and VEGF with SYN-2510, aiming to capitalize on promising immunotherapy trends. SYN-2510 ...

Iovance Biotherapeutics plans to add hundreds of new jobs at the Navy Yard in South Philadelphia as part of an effort to ramp ...

Iovance Biotherapeutics develops therapies that harness the power of tumor-infiltrating lymphocytes (TILs), immune cells that can target and destroy cancer cells. Iovance's TIL-based treatments ...